Stay updated with breaking news from Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
06.09.2022 - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced members of its management team will ...
Alpine Immune Sciences, Inc. , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced that, in... | August 18, 2022
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the second quarter ended June 30,...
Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $8.46 and traded as high as $8.94. Alpine Immune Sciences shares last traded at $8.80, with a volume of 60,111 shares changing hands. Analyst Upgrades and […]
- Just – Evotec Biologics will apply its fully integrated technology platform to develop an optimized commercial process for ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus... | August 10, 2022